MICB and COVID-19: If this evasion tactic occurs in vivo, it suggests a model whereby patients with increasing copies of the MICBG406A variant allele, which leads to reduced expression of MICB on pulmonary airway cells, would have less NK cell–mediated killing of SARS-CoV-2–infected or transformed cells, potentially limiting the immunopathology of COVID-19 that drives lung injury and mortality.